NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$21.21 +0.21 (+1.00 %)
(As of 11/13/2018 04:00 PM ET)
Previous Close$21.00
Today's Range$20.81 - $21.52
52-Week Range$14.40 - $21.65
Volume267,100 shs
Average Volume191,892 shs
Market Capitalization$998.68 million
P/E Ratio55.82
Dividend YieldN/A
Beta1.38
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMPH
Previous Symbol
CUSIPN/A
Phone909-980-9484

Debt

Debt-to-Equity Ratio0.10
Current Ratio2.02
Quick Ratio1.34

Price-To-Earnings

Trailing P/E Ratio55.82
Forward P/E Ratio212.10
P/E Growth9.84

Sales & Book Value

Annual Sales$240.18 million
Price / Sales4.09
Cash Flow$0.7185 per share
Price / Cash29.52
Book Value$7.34 per share
Price / Book2.89

Profitability

EPS (Most Recent Fiscal Year)$0.38
Net Income$4.50 million
Net Margins-2.33%
Return on Equity2.80%
Return on Assets2.02%

Miscellaneous

Employees1,644
Outstanding Shares46,260,000
Market Cap$998.68 million
OptionableOptionable

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How will Amphastar Pharmaceuticals' stock buyback program work?

Amphastar Pharmaceuticals announced that its board has authorized a stock buyback program on Thursday, August 10th 2017, which permits the company to buyback $20,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its stock is undervalued.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) released its earnings results on Thursday, November, 8th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. The firm had revenue of $75.54 million for the quarter, compared to the consensus estimate of $76.84 million. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. The company's quarterly revenue was up 30.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.07 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Amphastar Pharmaceuticals.

What price target have analysts set for AMPH?

4 equities research analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their forecasts range from $19.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $23.3333 in the next year. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.

What is the consensus analysts' recommendation for Amphastar Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amphastar Pharmaceuticals.

Has Amphastar Pharmaceuticals been receiving favorable news coverage?

Media stories about AMPH stock have trended neutral recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Amphastar Pharmaceuticals' key competitors?

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the folowing people:
  • Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 68)
  • Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 71)
  • Mr. Jason B. Shandell, Pres & Director (Age 44)
  • Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 50)
  • Mr. Rong Zhou, Exec. VP of Production Center (Age 59)

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.94%), Dimensional Fund Advisors LP (4.13%), Bank of New York Mellon Corp (0.91%), Rothschild & Co. Asset Management US Inc. (0.70%), Wells Fargo & Company MN (0.52%) and Renaissance Technologies LLC (0.40%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Which major investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Credit Suisse AG, Rothschild & Co. Asset Management US Inc., Strs Ohio and Comerica Bank. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Which major investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Martingale Asset Management L P, Renaissance Technologies LLC, Wells Fargo & Company MN, Bessemer Group Inc., Allianz Asset Management GmbH and Nisa Investment Advisors LLC. View Insider Buying and Selling for Amphastar Pharmaceuticals.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $21.21.

How big of a company is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals has a market capitalization of $998.68 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is http://www.amphastar.com.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]


MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  419
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel